Should HIV treatment start right away? new study tests timing
NCT ID NCT03825523
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study looked at whether starting antiretroviral therapy (ART) immediately (within 48 hours) versus waiting until an opportunistic infection is under control affects death rates in HIV/AIDS patients hospitalized with such infections. Researchers enrolled 114 adults with HIV and an opportunistic disease. The goal was to see if immediate treatment saves more lives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antiretroviral therapy (ART)
What this could lead to
If immediate ART works better, it could lead to a standard practice of starting HIV treatment right away in hospitalized patients with opportunistic infections, potentially saving more lives.
What could go wrong
This is a small completed study (114 participants) and results may not apply to all HIV patients, especially those with certain infections like cryptococcal meningitis. Timing of ART is just one factor in a complex disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro de Investigacion en Enfermedades Infecciosas
México, State of Mexico, 14080, Mexico